A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma

By Kefford Richard   Beith Jane   Hazel Guy   Millward Michael   Trotter James   Wyld David   Kusic Rada   Shreeniwas Revati   Morganti Adele   Ballmer Andrea   Segal Eleonor   Nayler Oliver   Clozel Martine  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 247-252

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas

By Stroppa Elisa   Bertuzzi Alexia   Comite Gabriele   Mussi Chiara   Lutman Romano   Barbato Alfredo   Santoro Armando  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 834-838

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma

By Ernst D   Eisenhauer Elizabeth   Wainman Nancy   Davis Mary   Lohmann Reinhard   Baetz Tara   Belanger Karl   Smylie Michael  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 569-575

Springer Publishing Company

Access to resources Recommend Favorite

A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma

By Lewis Karl   Thompson John   Weber Jeffrey   Robinson William   O'Day Steven   Lutzky Jose   Legha Sewa   Floret Simon   Ruvuna Francis   Gonzalez Rene  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 89-94

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

By Li Tianhong  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 741-748

Springer Publishing Company

Access to resources Recommend Favorite